Multiple colorectal liver metastases resection can offer long-term survival: The concept of a chronic neoplastic disease
- PMID: 36220666
- DOI: 10.1016/j.surg.2022.08.032
Multiple colorectal liver metastases resection can offer long-term survival: The concept of a chronic neoplastic disease
Abstract
Background: Resection for colorectal liver metastases has evolved significantly and, currently, there are no limits to the number of resected nodules. This study aimed to evaluate the outcomes and prognostic factors after liver resection for patients with ≥4 colorectal liver metastases, emphasizing long-term survival.
Methods: The study population consisted of 137 patients with ≥4 colorectal liver metastases out of a total of 597 patients with colorectal liver metastases who underwent curative intent liver resection from January 2010 to July 2019 in a single hepatobiliary center.
Results: The probability of overall and disease-free survival at 1, 3, and 5 years was 90.8%, 64.5%, 40.6%, and 37.7%, 19.3%, 18.1%, respectively. In a multivariate analysis for overall survival, the size of the largest metastatic nodule was the only unfavorable factor (P = .001). For disease-free survival, complete pathological response was a favorable factor (P = .04), and the following were negative factors: number of nodules ≥7 (P = .034), radiofrequency ablation during surgery (P = .04), positive primary tumor lymph nodes (P = .034), R1 resection (P = .011), and preoperative carcinoembryonic antigen >20 ng/mL (P = .015). After the first and second years of follow-up, 59 patients (45.3%) and 45 patients (34.6%), respectively, were not receiving chemotherapy. After 5 years of follow-up, 21 (16.1%) multimetastatic patients were chemotherapy-free.
Conclusion: A significant number of patients with multiple colorectal liver metastases will present long-term survival and should not be denied surgery. The long-term survival rates, even in the presence of recurrence, characterize a chronic neoplastic disease.
Copyright © 2022 Elsevier Inc. All rights reserved.
Comment in
-
Reverse-approach in colorectal cancer liver metastases: Patient selection is key.Surgery. 2023 Apr;173(4):1104-1105. doi: 10.1016/j.surg.2022.11.003. Epub 2022 Nov 29. Surgery. 2023. PMID: 36456396 No abstract available.
-
Invited commentary: Biology remains the ultimate arbiter of survival in metastatic colorectal cancer. Invited commentary on "Multiple colorectal liver metastases resection can offer long-term survival. The concept of a chronic neoplastic disease.".Surgery. 2023 Apr;173(4):991-992. doi: 10.1016/j.surg.2022.11.024. Epub 2022 Dec 15. Surgery. 2023. PMID: 36526488 No abstract available.
-
Reply to "Reverse-approach in colorectal cancer liver metastases: patient selection is key.".Surgery. 2023 Apr;173(4):1105-1106. doi: 10.1016/j.surg.2022.12.016. Epub 2023 Jan 10. Surgery. 2023. PMID: 36635194 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources